iBio Inc. closed 38.35% short of its 52-week high of $4.98, which the company achieved on March 28th.

The stock's fall snapped a two-day winning streak.

SAN DIEGO, Jan. 13, 2025 (GLOBE NEWSWIRE) -- (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, ...

San Diego-based iBio has signed a backloaded agreement with its existing partner AstralBio for a preclinical anti-myostatin antibody that it hopes can induce weight loss while retaining muscle mass.

In a regulatory filing, iBio (IBIO) disclosed that its director Antonio Parada bought 183.8K shares of common stock on January 10th in a total ...

SAN DIEGO, Jan. 02, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and ...

iBio in-licensed IBIO-600 from AstralBio for $750,000 in stock, with potential milestone payments of up to $28 million. IBIO-600 showed potent myostatin inhibition in preclinical studies ...

SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in ...

(RTTNews) - iBio, Inc. (IBIO), a preclinical stage biotechnology company, Thursday said it has in-licensed a long-acting anti-myostatin antibody, IBIO-600 from AstralBio, Inc. iBio has initiated a ...

iBio, Inc. has announced a collaboration with AstralBio Inc. to develop an innovative antibody targeting Activin E, a key factor in cardiometabolic disorders and obesity, using iBio's Machine ...